REPLY from BIEL management for my questions:
Thanks Paul, nice to hear back from you. All these wired messages were regularly followed by us. I would like to know few things like:
From management:
Company's thoughts about Share structure and Reverse split? It will burn all long investors like me since 2009.
We do not intend to do a reverse split until we have brokerage firm that will support the stock.
Plans to get into partnership deals? Any plans for share buy back? Is big pharma companies knocking BIEL door after the Approval? O don’t need names.
We are talking to several pharmaceutical companies that have retail over-the-counter sales capabilities. We are also proceeding with launching the products into drug stores, online and to health care professionals.
The current share price is not what expected after FDA approval, what steps needed?
We will engage a profession public relations when we have the time and money to get the investing community and the public better informed about the Company.
Thoughts on Dilution?
We only dilute to reinvest in the Company. On a comparative basis NeuroMetrix is a medical device developer in the chronic pain market and has spent $183 million compared to our less than $30 million.
Believe in your own DD. Experience: I once lost to a pumper with blind belief and the same pumper turned basher on another. Good Job!!. Moral: Do your own DD
